Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K+ channel inhibition in a histamine h3 receptor antagonist program

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 781-789

  Davenport, Adam J ^a   Möller, Clemens ^b   Heifetz, Alexander ^a   Mazanetz, Michael P ^a   Law, Richard J ^a   Ebneth, Andreas ^b   Gemkow, Mark J ^b  

^a EVOTEC UK LTD   (United Kingdom)

^b EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; HISTAMINE H3 RECEPTOR ANTAGONIST; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HIGH THROUGHPUT SCREENING; INHIBITION KINETICS; MOLECULAR DOCKING; PATCH CLAMP; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; DRUG DESIGN; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; HIGH-THROUGHPUT SCREENING ASSAYS; HISTAMINE H3 ANTAGONISTS; HUMANS; MODELS, MOLECULAR; PATCH-CLAMP TECHNIQUES; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650508749     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0322     Document Type: Article

References (43)

1. Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine-release mediated by a novel class (H-3) of histamine-receptor. Nature 1983; 302:832-837.
2. Schlicker E, et al.: Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1988; 337:588-590.
3. Schlicker E, et al.: Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340: 633-638.
4. Schlicker E, etal.: Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 1993;93:1-10.
5. Clapham J, Kilpatrick GJ: Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence of the possible existence for H3 receptor subtypes. Br J Pharmacol 1992;107:919-923.
6. Drutel G, et al.: Identification of rat H-3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 2001;59:1-8.
7. Martinezmir MI, et al.: Histamine receptor-H1, receptor-H2 and receptor-H3 visualized in the brain of human and nonhuman-primates. Brain Res 1990; 526:322-327.
8. Cannon KE, et al.: Immunohistochemical localization of histamine H-3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 2007;129:76-92.
9. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D: The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Dis Today 2009;14:509-515.
10. Ali SM, et al.: Design, synthesis, and structure-activity relationships of acetylene-based histamine H-3 receptor antagonists. J Med Chem 1999;42:903-909.
11. Celanire S, et al.: Histamine H-3 receptor antagonists reach out for the clinic. Drug Dis Today 2005;10:1613-1627.
12. Wijtmans M, Leurs R, de Esch I: Histamine H-3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16.7:967-985.
13. Cowart M, et al.: Medicinal chemistry and biological properties of non-imidazole histamine H-3 antagonists. Mini Rev Med Chem 2004;4: 979-992.
14. Sun MH, et al.: Synthesis and SAR of 5-amino-and 5-(aminomethyl) benzofuran histamine H-3 receptor antagonists with improved potency. J Med Chem 2005;48:6482-6490.
15. Zhao C, et al.: The alkaloid conessine and analogues as potent histamine H-3 receptor antagonists. J Med Chem 2008;51:5423-5430.
16. NagaseT, etal.: Synthesis, structure-activity relationships, and biological profiles ofa quinazolinone class of histamine H-3 receptor inverse agonists. J Med Chem 2008;51:4780-4789.
17. Lau JF, et al.: Ureas with histamine H-3-antagonist receptor activity-a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg Med Chem Lett 2006;16:5303-5308.
18. Hancock AA: The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H-3 antagonists/inverse agonists. Biochem Pharmacol 2006;71:1103-1113.
19. Roche O, Sarmiento RMR: A new class of histamine H-3 receptor antagonists derived from ligand based design. Bioorg Med Chem Lett 2007;17:3670-3675.
20. Lazewska D, etal.: Piperidine variations in search for non-imidazole histamine H3 receptor ligands. Bioorg Med Chem 2008;16:8729-8736.
21. Sander K, von Coburg Y, Camelin J-C, Ligneau X, Rau O, Schubert-Zsilavecz M, Schwartz J-C, Stark H: Acidic elements in histamine H3 receptor antagonists. Bioorg Med Chem Lett 2010;20:1581-1584.
22. Aronov AM: Predictive in silico modeling for hERG channel blockers. Drug Dis Today 2005;10:149-155.
23. Seierstad M, Agrafiotis DK: A QSAR model of hERG binding using a large, diverse, and internally consistent training set. Chem Biol Drug Des 2006;67:284-296.
24. [MOE] The Molecular Operating Environment: Version 2009.10, software available from Chemical Computing Group Inc., 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7. www.chemcomp.com.
25. Farid R, et al.: New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 2006;14:3160-3173.
26. Aronov AM, Goldman BB: A model for identifying HERG K+ channel blockers. Bioorg Med Chem 2004;12:2307-2315.
27. Diller DJ: In silico hERG modeling: challenges and progress. Curr Comput Aided Drug Des 2009;5:106-121.
28. Chau R-L, Dean RM: Electrostatic complementarity between proteins and ligands. Charge disposition, dielectric and interface effects. J ComputAided Mol Des 1994;8:513-525.
29. Heifetz A, Katchalski-Katzir E, Eisenstein M: electrostatics in protein-protein docking. Protein Sci 2002;1 1:571-587.
30. Grant JA, Pickup BT, Nicholls A: A smooth permittivity function for poisson-boltzmann solvation methods. J Comput Chem 2001;22:608-640.
31. Nicholls A, Grant JA: Molecular shape and electrostatics in the encoding of relevant chemical information. J Comput Aided Mol Des 2005;19:661-686.
32. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
33. Davenport AJ, Hallett DJ, Corsi M: Azetidines and cyclobutanes as Histamine H3 Receptor Antagonists. WO/2009/135842.
34. Aronov AM, Goldman BB: A model for identifying HERG K+ channel blockers. Bioorg Med Chem 2004;12:2307-2315.
35. Pearlstein RA, Vaz RJ, Kang J, Chen X-L, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D: Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-1835.
36. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationship for inhibition of human Ether-a-Go-Go-related gene potassium channel. JPET2002;301:427-434.
37. Cavalli A, Poluzzi E, De Ponti F, Recanatini M: Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers. J Med Chem 2002;45:3844-3853.
38. Brewer M: Development of a spectral clustering method for the analysis of molecular data sets. J Chem Inf Model 2007;47:1727-1733.
39. CCDC (2005). SILVER-A program for the post-processing of GOLD docking results. Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, England.
40. SIMCA-P, 11.0.0.0: Umetrics AB, Umea, Sweden, 2005. www.umetrics.com/ simca.
41. Mazanetz MP, Withers IM, Laughton CA, Fischer PM: QSAR Comb Sci 2009; 28:878-884.
42. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC: Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide. J Pharmacol Toxicol Methods 2010;61:178-191.
43. Deisemann H, Ahrens N, Schlobohm I, Kirchhoff C, Netzer R, Moller C: Effects of common antitussive drugs on the hERG potassium channel current. J Cardiovasc Pharmacol 2008;52:494-499.